IRIS UniCatt

Borghetti, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.775
NA - Nord America 2.665
AS - Asia 1.315
SA - Sud America 339
AF - Africa 68
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 6
Totale 7.196
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.584
IT - Italia 652
SG - Singapore 522
SE - Svezia 513
DE - Germania 372
FR - Francia 338
CN - Cina 329
BR - Brasile 309
PL - Polonia 229
IE - Irlanda 149
GB - Regno Unito 148
FI - Finlandia 102
ID - Indonesia 94
IN - India 85
UA - Ucraina 62
CA - Canada 56
RU - Federazione Russa 51
AT - Austria 31
BE - Belgio 31
HK - Hong Kong 30
TR - Turchia 29
IR - Iran 27
KR - Corea 27
NL - Olanda 26
AU - Australia 25
SA - Arabia Saudita 21
PK - Pakistan 18
BD - Bangladesh 16
CI - Costa d'Avorio 16
PH - Filippine 16
VN - Vietnam 15
CH - Svizzera 11
ES - Italia 11
IQ - Iraq 11
MX - Messico 11
MY - Malesia 11
AR - Argentina 10
CZ - Repubblica Ceca 10
EG - Egitto 10
MA - Marocco 10
TN - Tunisia 8
NP - Nepal 7
TW - Taiwan 7
UZ - Uzbekistan 7
ZA - Sudafrica 7
LT - Lituania 6
AE - Emirati Arabi Uniti 5
GR - Grecia 5
IL - Israele 5
KE - Kenya 5
NG - Nigeria 5
TH - Thailandia 5
CO - Colombia 4
DK - Danimarca 4
EU - Europa 4
JO - Giordania 4
JP - Giappone 4
PT - Portogallo 4
RO - Romania 4
CL - Cile 3
EC - Ecuador 3
JM - Giamaica 3
KG - Kirghizistan 3
MD - Moldavia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PE - Perù 3
PY - Paraguay 3
SD - Sudan 3
AL - Albania 2
BG - Bulgaria 2
BO - Bolivia 2
CM - Camerun 2
HN - Honduras 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MG - Madagascar 2
MM - Myanmar 2
MO - Macao, regione amministrativa speciale della Cina 2
OM - Oman 2
PA - Panama 2
TT - Trinidad e Tobago 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GL - Groenlandia 1
GT - Guatemala 1
IM - Isola di Man 1
KW - Kuwait 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
Totale 7.193
Salva come PNG Salva come JPEG
Città #
Chandler 626
Singapore 348
Ashburn 253
Kraków 209
Milan 163
Dublin 146
Rome 146
New York 143
Jakarta 93
San Mateo 79
Helsinki 68
The Dalles 62
Boston 60
Jacksonville 60
Ann Arbor 48
Los Angeles 48
Princeton 48
Wilmington 48
Frankfurt am Main 44
Marseille 43
Hefei 36
Redmond 33
Nanjing 32
Chicago 31
Beijing 30
Moscow 30
Brussels 28
Lancaster 27
Seoul 27
Cattolica 26
London 26
Düsseldorf 25
Hong Kong 24
Munich 24
Nuremberg 23
São Paulo 23
Boardman 22
Houston 21
Toronto 21
Vienna 21
Dearborn 20
Pune 20
Fairfield 19
Roubaix 18
Lawrence 17
Woodbridge 16
Abidjan 15
Amsterdam 15
Bremen 15
Portsmouth 15
Seattle 15
Augusta 14
Lauterbourg 14
North Bergen 14
Redwood City 13
Warsaw 13
Washington 13
Norwalk 12
Dammam 11
Izmir 11
Kish 11
Nürnberg 11
Santa Clara 11
Bexley 10
Paris 10
Turku 10
Andover 9
Belo Horizonte 9
Cambridge 9
Ottawa 9
Changsha 8
Falkenstein 8
Lahore 8
Phoenix 8
Sydney 8
Al Qatif 7
Guangzhou 7
Leawood 7
Padova 7
Tashkent 7
Cairo 6
Columbus 6
Delhi 6
Lappeenranta 6
Oggiono 6
Rio de Janeiro 6
Shenyang 6
Wroclaw 6
Zurich 6
Brooklyn 5
Buenos Aires 5
Cape Town 5
Ferrara 5
Guarulhos 5
Hyderabad 5
Jinan 5
Kathmandu 5
Nanchang 5
Naples 5
Olomouc 5
Totale 3.848
Salva come PNG Salva come JPEG
Nome #
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 458
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 184
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 181
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 180
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 174
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 150
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 150
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 148
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 147
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 135
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 133
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 125
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 125
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 120
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 118
Retinal capillary involvement in early post-COVID-19 patients: a healthy controlled study 116
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 114
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 108
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 105
Residual respiratory impairment after COVID-19 pneumonia 102
Psychological distress during the initial stage of the COVID-19 pandemic in an italian population living with HIV: An online survey 101
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 100
HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV 99
Shall we dance? Extending tango's results to clinical practice 94
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 94
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV 91
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 89
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 89
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 86
Impact of the COVID-19 Pandemic on Health Care Is Negatively Associated With Psychosocial Well-Being in an Italian Cohort of People Living With HIV 85
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 83
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line 83
Residual respiratory impairment after COVID-19 pneumonia 81
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 80
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice 77
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice 76
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 76
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study 76
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 75
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 75
Use of telehealth for HIV care in Italy: Are doctors and patients on the same page? A cross-sectional study 74
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital 74
Seroprevalence of sars-cov-2 antibodies in hiv-infected patients in rome, italy during the covid-19 outbreak 71
SARS-CoV-2 infection in a highly experienced person living with HIV 68
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 67
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 67
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 63
null 63
People Living with HIV in the COVID-19 Era: A Case Report 62
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting 60
Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life 59
Early use of tecovirimat in a young man with severe mpox skin lesions: a case report 59
No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy 59
Determinants of SARS-COV-2 seroconversion in a cohort of recovered patients 58
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic 58
HIV and vicarious stigma in a cohort of people living with HIV in Italy: What happens when the stigma is fueled by healthcare providers? 55
Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection 55
Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study 54
Focal status epilepticus as unique clinical feature of COVID-19: A case report 53
Off-label use of tocilizumab in patients with SARS-CoV-2 infection 50
People Living with HIV in the COVID-19 Era: A Case Report 49
Treatment of Aorto-iliac and Infrainguinal Vascular Infections with a Prefabricated Bovine Pericardial Graft 47
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors 47
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice 47
Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV 47
Short Communication: Efficacy and Safety of Dolutegravir plus Lamivudine as a First-Line Regimen in Clinical Practice 46
Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections 46
COVID-19 diagnosis does not rule out other concomitant diseases 45
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 45
Differences in the Long-term Impact of the COVID-19 Pandemic on the Mental Health and Professional Quality of Life of Resident and Specialist Physicians 44
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 44
No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine-Dolutegravir 44
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV 43
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 42
Atypical ductal hyperplasia on vacuum-assisted breast biopsy: a scoring system to predict the risk of upgrade to malignancy 41
The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors 40
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 40
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy 38
Real-life findings on the impact of the COVID-19 pandemic on HIV care 38
Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir-Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report 36
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 36
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study 35
Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study 35
Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen 34
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 34
Kaposi-like manifestations in a newly diagnosed aids transgendered patient with silicone embolism syndrome and disseminated tuberculosis 33
Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic 30
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 28
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic 27
Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital 27
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study 24
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 23
New insight of human-IgH 3′regulatory regions in immunoglobulins switch 22
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive 18
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: A real life multicentre cohort 15
Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB + RPV Regimen: A Prospective Observational Study 12
Assessing dengue seroprevalence among people living with HIV (PLWH) in rome, Italy: Insights from the 2023 Italian autochthonous outbreak 11
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive 8
Totale 7.333
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.232
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.232
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202018 0 0 0 0 0 0 0 0 0 0 0 18
2020/2021241 4 15 4 13 16 21 21 10 39 36 48 14
2021/2022714 35 21 16 74 20 23 65 116 31 56 89 168
2022/20232.072 212 261 181 332 210 273 87 158 221 56 62 19
2023/20241.149 44 229 37 102 62 187 80 33 41 58 141 135
2024/20252.198 29 54 263 88 177 94 150 122 307 192 483 239
Totale 7.333